Drug Profile
KITE 585
Alternative Names: BCMA CAR T-cell therapy - Kite Pharma; KITE-585Latest Information Update: 07 Nov 2022
Price :
$50
*
At a glance
- Originator Kite Pharma; National Cancer Institute (USA)
- Developer Kite Pharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 16 Sep 2022 KITE terminates a phase I trial in Multiple myeloma (Second-line therapy or greater) in USA (IV) due to lack of efficacy (NCT03318861)
- 31 Dec 2018 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in USA (IV)
- 31 Oct 2017 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT03318861)